Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thx Renee, appreciate that.
best to you,
who
yeah I'm aware
thanks, that's why I assumed this thing was done really. Financials here are just a cut n paste, change the date, and pay a small processing fee. Used to be company could just hang around as a shell and hopefully another company would use it to reverse into in order to streamline a public trading status.
I'm not sure what exactly happens now other then the SEC seems to have some equation to sweep them out of the market.
Like I said I'm just a holdover from long ago that holds some shares, but I've assumed no value for a very long time; at least since the reverse split that took out the rest of the holdouts. Other then me apparently.
This was always my favorite story from the 90's, so I keep it around but there have been whole years I've forgotten about it. Guess one day I'll hit my yahoo ticker symbol watch and it will probably just be gone.
SGUI is severely delinquent in filing their Financials and corporate filing obligations to the SEC. On Feb. 20, 2015 the SEC suspended 8 stocks from the Delinquent SEC Filers list, and it is likely that more delinquent Filers will be suspended.
Since Jan 1st, 2010 the SEC has suspended over 1290 stocks for Financials delinquencies. All of those Suspended stocks had their stock registrations revoked.
Shareholders should contact the company and pressure the Mgmt to file their delinquent Financials because ALL shareholders would be wiped out IF the SEC suspends the stock.
SGUI is on the list of delinquent filers:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110680509
think we
may have put the death curse on it. lol
best to you,
who's
Yes. This could get exciting fast. But I think a very things have to happen first or more of nothing happens
well volume generally doesn't lie
on the otc. Even just 30-50k per day is a significant flag here if it keeps up a bit, and if the 7 mil and change o/s count is still accurate well this would fly quick for certain. No reason to suspect it isn't, saw the 200 share buy the other day fire this thing like 200 percent north and it won't attract the flipper crowd with the bid ask spread here; that's a big bonus as well.
I got out of messing around with otcs over a decade ago, but jumped back in on an mj penny last spring for kicks, just letting that ride for a few years. Funny all the garbage flipping of these things in the 90's this is the only one I still just leave on my ticker. Such a cool concept & the Dr. had such an extraordinary past in this area couldn't help but root for him. World changing stuff really.
Too bad none of the minor or non medial apps for this couldn't generate the interest and capital to keep this rolling. I always thought this could possibly be the break thru on laminitis though I never got to discuss it with the Dr. or any of his officers. I've been involved some in the horse racing industry, this has been a death sentence forever, an injury that doesn't allow bloodflow to one of the hoofs. Derby winner Barbaro being the most recent example everyone would know, but it's a horrible injury that claims many. Something like that would be immediately world stopping stuff & I figured no humans plus it's really a try it situation; the horse is going to die the Kentucky crowd alone would drop millions if there was even an inkling of success. Well I'm sure no doctor or scientist, but Drees may just have had the key, who knows maybe he was John Galt.
My assumption was that the guy that took this operation over a few years ago was using it as a shell to potentially back a different company into at some point; one that wanted to cut through all the beauracratic nonsense to trade in the public arena, that happens sometimes. So maybe there is still some life to a blood substitute, that would be great. If anything breaks through I'll make myself moderator here, revamp the introduction, and get things up to date for the oncoming new crowd of faces/alias's.
best to you,
Yeah. Id like that. And you're right it has been quiet.
I hope that they will start putting some things together and share them in a press release.
oh, that's what happened
thanks for the heads up, I recall a pr a few years back but I don't recall that was the deal. Everything just went silent from there on to be honest I figured things just fell through. Believe I even emailed Mike about it, but he didn't have much info for me.
Well I'm glad I am not the only person that watches this stock, would be nice to get a whole new crew here again.
thanks for the info
regards
Sgui bought the IP of allp
nice
yeah I do remember allp now, and Baxter ok I think so. I recall the abbott labs and then the naval interest, admiral nelson I believe; which really got things interesting.
sheesh that really was quite a while back, good stuff. It seemed there were so many practical applications that wouldn't have required all the intense phase trials and such
Well to be honest it sure is nice to see reasonable volume 2 days in a row, even if not to the positive side.
Yes. IMO, This is a buy at these levels. SGUI.
Biopure was the company with bovine blood.
Northfield had refined out dated human blood.
SYBD was always pfc -- OXBT
ALLP pfc also
SGUI also pfc
I've been following this for years.
Years ago Baxter halted research.
seems maybe
someone is just liquidating. Who knows, surprised to even see any relevant volume here to be honest.
I'll have to take a look at things
when I get some time maybe this weekend. I have no idea what is going on with this type of product anymore, if anything.
It was interesting though, learned a lot I didn't know, and it sure seemed like Dr. Drees was really onto something.
best to you,
who
yeah I remember, the sybd crew
were the one's we were always bickering back and forth with, in good fun really. They had some animal blood mixed up in their product if I recall. I know they had some runs though, and they let us know it. We had some too.
So much money and time needed to ever get something like this through all the trial phases, to human testing and such. Probably close to impossible, but hey, that is what penny stocks are about really.
I just looked OXBT is now TENX.
I think I rem that stock. I got in SYBD in the early 90's. I did real well with it when I learned to play the swings. Then Chris stern got in as CEO and screwed up the company. It's now OXBT. But I don't think they are working on sync blood any longer.
I got out of Northfield just before the crash.
lmao
that's kind of true, one of the 1st pennies I ever followed that really had a good solid story. Dr. Thomas Drees had devoted his life really to the synthetic blood arena all the way back to the early 70's.
Had quite a big following, real good crew of pretty diligent followers, good communication, good due diligence. Ticker was sgnc back then, Abbot labs were interested & had some good runs.
To this day I think the good Dr. really had it figured out, just ended up being so much money for trials and all that, takes tons of cash and time, fda bureaucracy the whole nine yards.
Finally it began to just stagnate and fizzle, they did a significant reverse split and the whole crew & board & followers all hit the road right there. That had to be a decade or so ago.
I actually do still own a few thousand shares, less the 10k, but honestly it just stays on my ticker watch everyday more for sentimental reasons, it really was a good group of guys and a good story.
MBA type took over maybe 4 or 5 years ago, they stopped filing and I assume it's just a shell now. Not sure of Dr. Drees, I believe he would be well into his 90's now, really don't know anymore. Saw the 80k volume today, it's been a long time.
Someone is willing to sell at the bid price and that's driving the price lower.
I'm just inquiring on here. As to about hold long y'all been owning this stock?
think I heard a chirp
Crickets here
You must be his wife, then. Are you aware that what he did was illegal? He issued a press release stating that Sanguine Corp, a company whose business license was revoked in both Nevada and California (and therefore, it's unlawful to conduct ANY business under that name) was buying Oxygent from New Alliance Pharma. Let's see, the same guy who is the primary shareholder in Sanguine Corp and the only employee of New Alliance Pharma is selling a product from one to the other. Do you get it? He's selling the product to himself and no doubt, that was solely to drive up the share price for Sanguine Corp. You may have benefited, and maybe a few others too, but who benefited the most? You don't need to be a college graduate to figure this one out.
Thanks for the warning, but I was holding for a couple weeks and then left a happy girl :)
Be very careful with this one. The guy who heads it up has a high school diploma, although he reported in the last SEC filing that he has a PhD and an MBA. Also makes a lot of other grandiose statements about himself, like that he made his money as a pitcher for the Minnesota Twins, and what he's accomplished but it's all pure nonsense. He also threatened me when I demanded money that he owes me (I now have a judgment against him, and that's all in the public record in the State of Delaware) and sent the police to my house as an intimidation tactic. He now goes around slandering me, stating that he has me on record as acting insane. He he has nothing on record of any sort. I think it's a classic case of transference. (No doubt he'll have to look that word up.)
Light volume so far...Nice & quiet :)
SGUI
Yes join tr party
Looking good
Wowwwww called this like a boss stocks
What's up with this did ur crew run this ticker?
Sanguine Enters Letter of Intent
ATLANTA, GA, Dec 05, 2012 (MARKETWIRE via COMTEX) -- Sanguine Corporation (OTCBB: SGUI), an innovator in perfluorocarbon ("PFC") based therapies, is pleased to announce that it has entered into a Letter of Intent (LOI) to purchase New Alliance Pharmaceuticals, Inc. ("New Alliance"). New Alliance holds an exclusive license for Oxygent(TM), the most clinically advanced perfluorocarbon (PFC) product in the world, with 20 clinical studies and ~250 preclinical studies already completed.
Mr. Frank Marra, the president of SGUI, said, "We are delighted to report to our shareholders that, after a careful due diligence, we have entered into an LOI to acquire New Alliance Pharmaceuticals, licensee of Oxygent. The acquisition of Oxygent is a potential game-changer for us. The extensive clinical history of Oxygent will put us at the forefront of oxygen therapy research and development. We are very much looking forward to closing this transaction and moving to the next phase of our plan." Mr. Marra added that he expects the acquisition to close by the first quarter of 2013.
About Sanguine Corp: Sanguine Corporation is focused on pioneering the development and commercialization of innovative PFC based therapies and medical devices. Sanguine's philosophy is to develop products that have a sound scientific basis, a demonstrated proof of concept and adhere to the highest industry standards of product development. The Company achieves its designated objectives through two primary means: (1) the employment organic methodologies, and (2) strategic alliances through carefully managed partnerships with well positioned companies, universities, research institutions and government agencies.
Cautionary Note Regarding Forward-Looking Statements:
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
For information related to the Sanguine Corp., contact Investor Relations:
Michael Dancy
801-746-3570
Email Contact
SOURCE: Sanguine Corporation
SGNC 1-20 Reverse Split
14:09 9/10/2008 SGNC Sanguine Corporation Common Stock SGUI Sanguine Corporation New Common Stock 1-20 R/S **
http://otcbb.com/asp/dailylist_detail.asp?d=09/09/2008&mkt_ctg=ALL
good lord reverse split; they have now squeezed all hope out of this thing.
Sanguine Corporation Adds to its Management Advisory Team
6:00 AM ET - BusinessWire
Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce the selection of Gary L. Corderman to the Company's Management Advisory team. Mr. Corderman has over 20 years of investment experience. Corderman joined Halbert, Hargrove/Russell LLC, located in Long Beach, California in 1998. He has built his practice and service team with a focus on working with both institutional sized family/trust accounts (many of which are multi-generational) and other investment accounts that have a fiduciary nature, such as pension plans and endowment or foundation relationships.
Previously Mr. Corderman worked extensively with consulting and marketing teams that focused on both institutional as well as individual accounts. He spent time most recently with Lord Abbett Mutual Funds but also Watson Wyatt Consulting and Fidelity Investments Institutional. His duties have included a broad range of responsibilities from working directly on individual and institutional client relationships to public speaking engagements. He was also responsible for instructing and educating brokers and account executives at brokerage firms about structuring portfolios for institutional clients. Mr. Corderman received his Bachelor's degree in Business Management from Miami University and his Master of Business Administration from the Fuqua School of Business at Duke University.
Dr. Thomas C. Drees, Ph.D., CEO, added, "We continue to build our management team with talent in the areas of finance, investment and healthcare. As we continue to execute our strategy of building a company focused on long-term growth opportunities, we look toward Gary as becoming an integral part of our ability to garner Institutional support. We expect Gary's experience will aid significantly with our previously announced acquisition strategies."
About Sanguine
Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2 that consists of perfluoro-decalin molecules, purified water, and a proprietary synthetic - patent pending fluorinated surfactant to hold the emulsion together.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
For Sanguine Corporation Michael Dancy, 801-746-3570 (Investor Relations) medancy@allwest.net
Recent Market News
May 2, 2008
I check in here once in a while due to a past loyalty and I just noticed your post. This link will give you an idea of when Dr. Drees went public. It’s not definitive but it is a place to start.
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=4852839
ok so i have tried to find out when this company actually started publically trading and i have had some issues.
The closest i have come so far is over 6 years ago? does anyone have a clue as to anything exact?
Sanguine Corporation Receives Update from PHER-O2 Manufacturer
6:00 AM ET - BusinessWire
Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce that a meeting was held at the office in West Chester, Pennsylvania, with the Company's GMP pharmaceutical manufacturer of PHER-O2 to discuss the product's progress and stage of development. With the recent supply of PHER-O2 to a European medical research group for intravenous development and evaluation, Sanguine management elected to discuss the progress of PHER-O2's master drug file, improved manufacturing and requirements necessary for long term supply of product. The details of the meeting were confidential, however both companies' management were quite pleased with the progress and future of PHER-O2 as a transport medium for transplantable materials.
According to Sanguine's spokesperson, Mr. Frank Marra, "The manufacturer is one of Europe's most respected pharmaceutical groups with medical device expertise in the areas of bedside and ambulatory infusion technology, infusion disposables, enteral application technology, auto-transfusions, blood collection and processing. With the intravenous pre-clinical evaluation progressing well, and with the company's readiness to complete the master drug file necessary for a 510(k) device application, it was important to meet with our product manufacturer to discuss ways to expedite avenues to product sales. We expect PHER-O2 to be an integral part of the Company's future, once the 510(k) approval is complete."
About Sanguine
Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2, that consists of perfluoro-decalin molecules, purified water, and a proprietary synthetic - patent pending fluorinated surfactant to hold the emulsion together.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
For Sanguine Corporation Michael Dancy, 801-746-3570 (Investor Relations) medancy@allwest.net
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
132
|
Created
|
06/09/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |